Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Kajsa Strååt, Eva Isaksson, Ann Charlotte Laska, Elisabeth Rooth, Emma Svennberg, Signild Åsberg, Per Wester, Johan Engdahl
BACKGROUND: Atrial fibrillation (AF) screening after ischemic stroke or transient ischemic attack (TIA) is given high priority in clinical guidelines. However, patient selection, electrocardiogram (ECG) modality and screening duration remains undecided and current recommendations vary. METHODS: The aim of this study was to investigate the clinical practice of AF screening after ischemic stroke or TIA at Swedish stroke units. In collaboration with the stakeholders of the Swedish Stroke Register (Riksstroke) a digital survey was drafted, then tested and revised by three stroke consultants...
April 11, 2024: BMC Neurology
#22
REVIEW
Stephan von Haehling, Birgit Assmus, Tarek Bekfani, Elke Dworatzek, Frank Edelmann, Djawid Hashemi, Kristian Hellenkamp, Tibor Kempf, Philipp Raake, Katharina A Schütt, Rolf Wachter, Paul Christian Schulze, Gerd Hasenfuss, Michael Böhm, Johann Bauersachs
The aetiology of heart failure with preserved ejection fraction (HFpEF) is heterogenous and overlaps with that of several comorbidities like atrial fibrillation, diabetes mellitus, chronic kidney disease, valvular heart disease, iron deficiency, or sarcopenia. The diagnosis of HFpEF involves evaluating cardiac dysfunction through imaging techniques and assessing increased left ventricular filling pressure, which can be measured directly or estimated through various proxies including natriuretic peptides. To better narrow down the differential diagnosis of HFpEF, European and American heart failure guidelines advocate the use of different algorithms including comorbidities that require diagnosis and rigorous treatment during the evaluation process...
April 11, 2024: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
#23
JOURNAL ARTICLE
Victoria Ivensky, Pitchou Zonga, Gabriel Dallaire, Louis-Charles Desbiens, Annie-Claire Nadeau-Fredette, Guy Rousseau, Rémi Goupil
BACKGROUND: Although blood pressure (BP) control is critical to prevent cardiovascular diseases, hypertension control rates in Canada are in decline. OBJECTIVE: To assess this issue, we sought to evaluate the differences in antihypertensive medication prescription profiles in the province of Quebec between 2009 and 2021. DESIGN: This is a retrospective cohort study. SETTING: We used data from the CARTaGENE population-based cohort linked to administrative health databases...
2024: Canadian Journal of Kidney Health and Disease
#24
JOURNAL ARTICLE
Charlotte J Lenting, E P J Petra Wijtvliet, Tim Koldenhof, Bram Bessem, Nikki A H A Pluymaekers, Michiel Rienstra, Richard J Folkeringa, Patrick Bronzwaer, Arif Elvan, Jan Elders, Raymond Tukkie, Justin G L M Luermans, Sander M J Van Kuijk, Jan G P Tijssen, Isabelle C Van Gelder, Harry J G M Crijns, Robert G Tieleman
INTRODUCTION: Long-term endurance exercise is suspect to elevate the risk of atrial fibrillation (AF),but little is known about cardiovascular outcome and disease progression in this subgroup of AF patients. We investigated whether previous exercise level determines cardiovascular outcome. METHODS: In this post hoc analysis of the RACE 4 randomized trial, we analyzed all patients with a completed questionnaire on sports participation. Three subgroups were made based on lifetime sports hours up to randomization and previous compliance to the international physical activity guidelines...
April 10, 2024: Medicine and Science in Sports and Exercise
#25
JOURNAL ARTICLE
Dominik Linz, Jason G Andrade, Elena Arbelo, Giuseppe Boriani, Guenter Breithardt, A John Camm, Valeria Caso, Jens Cosedis Nielsen, Mirko De Melis, Tom De Potter, Wolfgang Dichtl, Søren Zoega Diederichsen, Dobromir Dobrev, Nicolas Doll, David Duncker, Elke Dworatzek, Lars Eckardt, Christoph Eisert, Larissa Fabritz, Michal Farkowski, David Filgueiras-Rama, Andreas Goette, Eduard Guasch, Guido Hack, Stéphane Hatem, Karl Georg Haeusler, Jeff S Healey, Hein Heidbuechel, Ziad Hijazi, Lucas H Hofmeister, Leif Hove-Madsen, Thomas Huebner, Stefan Kääb, Dipak Kotecha, Katarzyna Malaczynska-Rajpold, José Luis Merino, Andreas Metzner, Lluís Mont, Ghulam Andre Ng, Michael Oeff, Abdul Shokor Parwani, Helmut Puererfellner, Ursula Ravens, Michiel Rienstra, Prashanthan Sanders, Daniel Scherr, Renate Schnabel, Ulrich Schotten, Christian Sohns, Gerhard Steinbeck, Daniel Steven, Tobias Toennis, Stylianos Tzeis, Isabelle C van Gelder, Roderick H van Leerdam, Kevin Vernooy, Manish Wadhwa, Reza Wakili, Stephan Willems, Henning Witt, Stef Zeemering, Paulus Kirchhof
AIMS: Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated with a low risk of AF-related complications. The aim of this document is to summarize the key outcomes of the 9th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA). METHODS AND RESULTS: Eighty-three international experts met in Münster for 2 days in September 2023...
March 30, 2024: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
#26
REVIEW
Massimo Baudo, Fabrizio Rosati, Elisabetta Lapenna, Lorenzo Di Bacco, Stefano Benussi
Current guidelines recommend concomitant surgical ablation (SA) of atrial fibrillation (AF) in the context of mitral valve disease. A variety of energy sources have been tested for SA to perform effective transmural lesions reliably. To date, only radiofrequency and cryothermy energies are considered viable options. The gold standard for SA is the Cox-Maze ablation set, especially for non-paroxysmal AF (nPAF), with the aim of interrupting macro-reentrant drivers perpetuating AF, without hampering the sinus node activation of both atria, and to maintain the atrioventricular synchrony...
March 29, 2024: Annals of Cardiothoracic Surgery
#27
JOURNAL ARTICLE
Sedighe Sadeghi, Mojtaba Jokar, Seyed Mostafa Seyed Hossieni Tezerjani, Hasan Haghaninejad, Elahe Zare, Mahmood Emami Meybodi, Mohammadtaghi Sareban Hassanabadi, Masoud Mirzaei, Hamidreza Mohammadi, Forough Sadat Tabatabaei
BACKGROUND AND AIMS: Electrocardiography (ECG) is a widely accessible, noninvasive, and cost-effective diagnostic instrument used to evaluate patients with suspected heart failure (HF). The aim of this study is to investigate electrocardiographic changes in patients with different stages of HF in a random population of Yazd city. METHODS: This prospective cross-sectional study included 319 individuals, randomly selected, aged 40 years and more, registered in the Yazd Health Study was conducted from March 2022 to May 2023 at Afshar Hospitals...
April 2024: Health Science Reports
#28
Bharat K Kantharia, Zaw Win Tun, Arti N Shah
Pulmonary vein (PV) isolation (PVI) ablation as the first-line therapy for atrial fibrillation (AF) and repeat PVIs for patients who had symptomatic improvement with the index PVI but who develop AF recurrence are directed by practice guidelines. How many catheter ablation (CA) procedures constitute the definition of "multiple" ablations is not known. Whether atrial tachyarrhythmias (AF, atrial tachycardia [AT], atrial flutter [AFL]) that occur post-ablation are due entirely to the proarrhythmic effects of CA or a continuum of the arrhythmia spectrum from the underlying atriopathy is debatable...
March 2024: Journal of Innovations in Cardiac Rhythm Management
#29
JOURNAL ARTICLE
Min Choon Tan, Qi Xuan Ang, Yong Hao Yeo, Boon Jian San, Ramzi Ibrahim, Sze Jia Ng, Jian Liang Tan, Jasjit Walia, Addi Suleiman, Joaquim Correia
Sarcoidosis is a disease that involves multiple organs, including the cardiovascular system. While cardiac sarcoidosis has been increasingly recognized, the impact of sarcoidosis on atrial fibrillation (AF) is not well established. This study aimed to analyze the impact of sarcoidosis on in-hospital outcomes among patients who were admitted for a primary diagnosis of AF. Using the all-payer, nationally representative Nationwide Readmissions Database, our study included patients aged ≥18 years who were admitted for AF between 2017-2020...
March 2024: Journal of Innovations in Cardiac Rhythm Management
#30
JOURNAL ARTICLE
Chidebelum O Nnake, Alondra Concepcion-Gonzalez, Matan S Malka, Emma Berube, Anne Ferris, Nicole Bainton, Michael G Vitale, Benjamin D Roye
OBJECTIVE: Severe scoliosis can affect thoracic organs, potentially leading to cardiovascular abnormalities. Thus, echocardiograms have been suggested for use in preoperative screening in patients with significant scoliosis. However, the utility of preoperative heart screenings in patients without known or suspected heart problems is not well understood. This study aims to find the incidence of cardiac findings in patients with severe scoliosis ≥90° without cardiac history...
April 8, 2024: Journal of Pediatric Orthopedics
#31
REVIEW
Taw Moe Myat San, Khin Phue Phue Han, Muhammad Ismail, Lei Myint Thu, Myat Soe Thet
BACKGROUND: Atrial fibrillation (AF) and pericardial effusion are notable complications following coronary artery bypass grafting (CABG), contributing to increased morbidity and healthcare costs. Posterior pericardiotomy has been proposed to mitigate these complications. This systematic review and meta-analysis aim to evaluate the efficacy of posterior pericardiotomy in reducing postoperative AF and pericardial effusion in isolated CABG patients. MATERIALS AND METHODS: A comprehensive literature search, adhering to PRISMA guidelines, was conducted across PubMed, MEDLINE via Ovid, Embase, Scopus, the Central Register of Controlled Trials (CENTRAL), and ClinicalTrials...
March 30, 2024: Cardiovascular Revascularization Medicine: Including Molecular Interventions
#32
JOURNAL ARTICLE
Esther Vanderstuyft, Julie Hias, Laura Hellemans, Lucas Van Aelst, Jos Tournoy, Lorenz Roger Van der Linden
BACKGROUND: Atrial fibrillation occurs in nearly half of geriatric inpatients and is a major cause of morbidity and mortality. Suboptimal anticoagulation use is an important concern in this population. This study aimed to evaluate the appropriateness of antithrombotic therapies in this patient cohort. METHODS: A retrospective analysis was conducted on the geriatric wards of a teaching hospital in Belgium, on a background of clinical pharmacy services. The first 90 atrial fibrillation patients from 2020 to 2022 were included if they received an oral anticoagulant...
April 5, 2024: European Journal of Hospital Pharmacy. Science and Practice
#33
JOURNAL ARTICLE
Elizabeth M Foster, James C Coons, Elena A Puccio, Danine Sullinger, Rachel Ibrahim, Joseph Ibrahim, Gavin W Hickey, Edward Horn, Vincent Mosesso, Ryan M Rivosecchi
BACKGROUND: Despite atrial fibrillation guideline recommendations, many patients with heart failure with reduced ejection fraction (EF) continue to receive IV diltiazem for acute rate control. OBJECTIVE: Our institution recently implemented a clinical decision support system (CDSS)-based tool that recommends against the use of diltiazem in patients with an EF ≤ 40%. The objective of this study was to evaluate outcomes of adherence to the aforementioned CDSS-based tool...
April 3, 2024: Annals of Pharmacotherapy
#34
JOURNAL ARTICLE
J Hunter Mehaffey, Mohammad Kawsara, Vikrant Jagadeesan, Dhaval Chauhan, J W Awori Hayanga, Christopher E Mascio, Lawrence Wei, J Scott Rankin, Ramesh Daggubati, Vinay Badhwar
BACKGROUND: Societal guidelines support atrial fibrillation (AF) treatment during surgical aortic valve replacement (SAVR). Recently, many low-intermediate risk patients with AF are managed by transcatheter aortic valve replacement (TAVR). Therefore, we evaluated longitudinal outcomes in these populations. METHODS: The United States Centers for Medicare and Medicaid Services inpatient claims database was evaluated for all beneficiaries with AF undergoing TAVR or SAVR with/without AF treatment (2018-20)...
April 1, 2024: Annals of Thoracic Surgery
#35
JOURNAL ARTICLE
Shobhit P Joseph, Shohiab U R Mirza, Jesu Krupa, Shruti I Varghese, Gayathri B Kartha, Oommen K George, Paul V George, John Jose, Viji S Thomson
OBJECTIVES: This retrospective study sought to determine the feasibility of transcatheter atrial septal defect device closure in patients less than 15 kg, as well as to assess complication rates and the reasons for unsuccessful device closure. BACKGROUND: In general, the risks associated with transcatheter atrial septal defect device closure are believed and reported to be relatively low, but the evidence stems from trials involving adults and older children. Current guidelines do not recommend atrial defect closure in device closure in children <15 kg, due to limited data available for feasibility and safety of device closure in this group of patients...
2024: Journal of the Saudi Heart Association
#36
JOURNAL ARTICLE
Zheng Li, Rui Zhao, Qunling Zhang, Yihui Shen, Xianhong Shu, Leilei Cheng
BACKGROUND: Left ventricular global longitudinal strain (LVGLS) has been recommended by current guidelines for diagnosing anthracycline-induced cardiotoxicity. However, little is known about the early changes in left atrial (LA) morphology and function in this population. Our study aimed to evaluate the potential usefulness of LA indices and their incremental value to LVGLS with three-dimensional echocardiography (3DE) in the early detection of subclinical cardiotoxicity in patients with lymphoma receiving anthracycline...
April 2024: Echocardiography
#37
JOURNAL ARTICLE
Sophia Lee, Jeremy A Ross, Ali Zalpour, Jason T Henry, Cristhiam M Rojas Hernandez
Venous thromboembolism (VTE) and stroke carry significant mortality and morbidity in cancer patients. Direct oral anticoagulants (DOACs) have been demonstrated to be effective for the treatment of VTE and prevention of stroke in atrial fibrillation (AF). Bleeding rates are variable and are based on the cancer type and the patient's specific risk factors. There are approved specific antidotes for DOAC-associated bleeding. Other strategies are available for bleeding reversal, including the use of prothrombin complex concentrate (PCC)...
March 31, 2024: Journal of Thrombosis and Thrombolysis
#38
JOURNAL ARTICLE
Zhike Yin, Yongmei Deng, Zixiao Li, Hongqiu Gu, Qi Zhou, Yongjun Wang, Chunjuan Wang
OBJECTIVES: This study aimed to describe the frequency, determinants and outcomes for assessment of patients who had an acute ischaemic stroke (AIS) for rehabilitation during hospitalisation in China. DESIGN: A registry-based retrospective observational study. STUDY DESIGN AND SETTINGS: Data regarding assessment or rehabilitation were extracted from the Chinese Stroke Center Alliance database from 1 August 2015 to 31 July 2019. Univariate and multivariate analyses were conducted to identify patient and hospital characteristics associated with rehabilitation assessment during acute hospitalisation as well as discharge outcomes...
March 29, 2024: BMJ Open
#39
JOURNAL ARTICLE
Juliane Frydenlund, Jan Brink Valentin, Marie Norredam, Lars Frost, Sam Riahi, Kristian Hay Kragholm, Henrik Bøggild, Gregory Y H Lip, Søren Paaske Johnsen
BACKGROUND: Atrial fibrillation (AF) is the most common sustained arrhythmia and results in a high risk of stroke. The number of immigrants is increasing globally, but little is known about potential differences in AF care across migrant populations. AIM: To investigate if initiation of oral anticoagulation therapy (OAC) differs for patients with incident AF in relation to country of origin. METHODS: A nationwide register-based study covering 1999-2017...
March 29, 2024: Open Heart
#40
JOURNAL ARTICLE
Mohamad Raad, Haran Yogasundaram, Justice Oranefo, Gustavo Guandalini, Timothy Markman, Matthew Hyman, Robert Schaller, Gregory Supple, Rajat Deo, Saman Nazarian, Michael Riley, David Lin, Fermin Garcia, Sanjay Dixit, Andrew E Epstein, David Callans, Francis E Marchlinski, David S Frankel
BACKGROUND: Premature ventricular complexes (PVCs) are common and associated with worse outcomes in patients with heart failure. Class 1C antiarrhythmic drugs (AADs) effectively suppress PVCs, but guidelines currently restrict their use in structural heart disease. OBJECTIVES: This study aimed to assess the safety and efficacy of class 1C AADs in patients with nonischemic cardiomyopathy (NICM) and implantable cardioverter-defibrillators (ICDs). METHODS: All patients with NICM and an ICD treated with flecainide or propafenone at the Hospital of the University of Pennsylvania between 2014 and 2022 were identified...
March 5, 2024: JACC. Clinical Electrophysiology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
